Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, is delighted to an...
Wolters Kluwer Health announced it has signed and completed the acquisition of Invistics Corporation (Invistics), a U.S.-based provider of cloud-base...
In this collaboration, Iktos’ de novo generative design technology in combination with Curreio’s state-of-the-art cryo-EM platform will be used...
Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approved Across all clinical ...
SCIEX, a global leader in life science analytical technologies, launches the Intabio ZT system, the first fully-integrated microfluidic chip-based platform...
“We are very excited that Bristol Myers Squibb selected MEDiC as a collaborator to advance its oncology discovery programs,” said Kyuho Han, Ph...
“We are committed to firmly establishing BullFrog AI as the undisputed leader in artificial intelligence-driven drug development,” said Vin Sin...
Responds to global demand for biosafety testing for drug development and commercialization Expansion creates nearly 500 new jobs in Glasgow and Stirling...
This marks the second BTD granted to olverembatinib by the CDE, with the first one granted in March 2021 for the treatment of patients with chronic-phase c...
SKYCovion is the world’s first-ever vaccine developed using the RoseTTAFold, a software tool that uses deep learning. SK bioscience has appl...
Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP...
Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...
First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
© 2025 Biopharma Boardroom. All Rights Reserved.
